A huge turnout was expected for the funeral Sunday of slain Hezbollah leader Hassan Nasrallah, as the Lebanese militant group ...

Israeli hostage Shiri Bibas's community confirmed her death Saturday after new remains were returned from Gaza, as the seventh hostage-prisoner exchange under a fragile Gaza ceasefire was set to go ...

The NoVo Foundation, the charitable organization controlled by Peter and Jennifer Buffett, gave out at least $45 million to regional organizations, schools, activist groups, farm programs, food ...

A large crowd took to the streets of Berlin on Saturday in opposition to a demonstration staged by around 100 neo-Nazis. More ...

Palestinian militants on Saturday freed two Israeli hostages, among the last live captives eligible for release under the ...

A total of 19,012 Heads of Household (KIR/Ketua Isi Rumah) have received the KAD Perak Sejahtera (KPS) assistance so far, which is part of the state's efforts to help the low-income group. Menteri ...

The family of Israeli hostage Shiri Bibas confirmed on Saturday receipt of her remains, just ahead of the seventh ...

Arab leaders met in Riyadh on Friday to craft a plan for Gaza's post-war reconstruction to counter Donald Trump's proposal ...

日前，Innate Pharma公司宣布，其开发的针对KIR3DL2的单抗lacutamab获得美国食品药品监督管理局（FDA）授予的突破性疗法认定（BTD）。此疗法意在治疗经过至少两种系统性治疗（包括mogamulizumab）后复发或难治性的成人Sézary综合征患者。

Lacutamab是一款潜在“first-in-class”的人源化KIR3DL2靶向抗体，能够诱导细胞毒性产生，目前处于治疗CTCL的临床试验阶段。KIR3DL2作为KIR家族的抑制性受体，在正常组织中的表达受到严格限制，但表达于约65%的所有CTCL亚型患者，在某些侵袭性CTCL亚型中（尤其是Sézary综合征患者）表达率可高达90%，而在蕈样肉芽肿和外周T细胞淋巴瘤患者中则约为50%。